 |
Adam Bonislawski is the editor of GenomeWeb's ProteoMonitor. He covers proteomics and life science mass spectrometry. E-mail Adam Bonislawski and follow his GenomeWeb Twitter account at @ProteoMonitor. |
Crescendo Publishes Validation Study Supporting Use of Vectra DA for Assessing RA Activity
July 06, 2012
Crescendo Publishes Validation Study Supporting Use of Vectra DA for Assessing RA Activity
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Big Names Join Clinical Proteomics Push in 2011, Offering Ray of Optimism Amidst Difficult Year
January 6, 2012 / ProteoMonitor - Crescendo Presents Data Indicating Vectra DA RA Test May Help ID Patients in Remission
June 8, 2012 / ProteoMonitor - New York Clears Crescendo Bio to Offer RA Test
April 18, 2013 / GenomeWeb Daily News - Dx Developers' Sales Pitch to Pharma Could be Key Factor in Marketing Some Tests
February 15, 2012 / Pharmacogenomics Reporter - Myriad Moving Eight Protein-Based Tests to Market; Priorities Include AD, Kidney Damage, Colon Cancer
November 4, 2011 / ProteoMonitor